Based on positive early data available for the first five patients in a phase 1/2a clinical study of OpRegen, Lineage Cell Therapeutics announced it would open new clinical sites to accelerate patient enrollment.
OpRegen is under study as a retinal epithelium transplant therapy in patients with advanced dry age-related macular degeneration with geographic atrophy. The study aims to evaluate the safety and efficacy of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line in 24 patients divided into four cohorts. The first three (Read more...)
Uncategorized